Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial
Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patien
Atara Biotherapeutics Announces Memorial Sloan Kettering Cancer Center’s Notification To FDA Of A Fatal Serious Adverse Event Associated With Phase 1, MSK-Conducted Study Of ATA2271
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, developing transformative therapies for patients with cancer and autoimmune diseases, today reported Memorial Sloan Kettering Cancer
Fujifilm To Buy Cell Therapy Plant From Atara For $100M
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Atara Biotherapeutics Highlights New Nature Study Titled ‘Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM’
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple
Be The Match BioTherapies, Atara Biotherapeutics Announce Multi-Year Partnership Extension
Relationship Will Leverage Be The Match BioTherapies' Expertise and Expansive Donor Registry to Provide Healthy Donor Cells in Support of Atara's Allogeneic T-cell Platform
Be The Match BioTherapies and Atara
JP Morgan Maintains Overweight on Atara Biotherapeutics, Raises Price Target to $27
JP Morgan analyst Anupam Rama maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Overweight and raises the price target from $26 to $27.
20 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
How Bad Are Atara Biotherapeutics’s Earnings? | Return On Capital Employed
Atara Biotherapeutics (NASDAQ:ATRA) brought in sales totaling $5.37 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 0.96%, resulting in a loss of $84.81 million.